India's PLI Scheme for Pharma: How It's Reshaping API Manufacturing
India's Production-Linked Incentive (PLI) scheme for the pharmaceutical sector is a government policy that has received significant attention from the global pharma industry. For international buyers, understanding what the PLI scheme is, what it covers, and what it means for the supply chain is useful background for long-term sourcing strategy.
---
What Is the PLI Scheme?
The PLI scheme is a government of India initiative that provides financial incentives to manufacturers based on incremental sales over a base year — "produce more, earn an incentive." It was introduced across multiple sectors from 2020–21 as part of India's broader Atmanirbhar Bharat (self-reliant India) economic programme.
For the pharmaceutical sector, there are two separate PLI schemes with different objectives:
PLI Scheme 1: Key Starting Materials (KSMs), Drug Intermediates, and APIs
Administered by: Department of Pharmaceuticals (DoP) Objective: Reduce India's dependence on imported APIs and chemical intermediates — particularly from China, which historically supplied a large share of India's API imports in certain categories What it covers: A defined list of bulk drugs / APIs in categories including: - Fermentation-based APIs (penicillin, erythromycin, etc.) - Chemical synthesis-based APIs - Key starting materials for critical drug categories How it works: Manufacturers who invest in new domestic production capacity for listed KSMs/APIs receive incentives (as a percentage of incremental sales) for a defined period, encouraging greenfield and brownfield capacity creation.PLI Scheme 2: Pharmaceuticals (Formulations)
Administered by: Department of Pharmaceuticals (DoP) Objective: Promote manufacturing of high-value / complex pharmaceutical formulations — moving India's export profile beyond generic commodity formulations What it covers: Three product categories: - Category 1: Biopharmaceuticals (biosimilars, recombinant proteins, vaccines) - Category 2: Complex generics, patented drugs going off-patent, other specified products - Category 3: Drugs not manufactured in India and repurposed drugs---
Why This Matters for International Buyers
1. API supply securityThe PLI scheme for APIs/KSMs is building domestic Indian production capacity in categories where India was previously import-dependent. For buyers of formulations, this means the underlying raw materials for those formulations are increasingly being sourced within India — potentially improving supply chain resilience and reducing raw material price volatility tied to Chinese API market conditions.
2. Product range expansionThe formulations PLI is designed to incentivise Indian manufacturers to produce more complex, higher-value products — biosimilars, specialty generics, difficult-to-manufacture formulations. Over time, this should expand the range of sophisticated pharmaceutical products available from Indian manufacturers for export.
3. New capacity coming onlinePLI incentives create a pull for new manufacturing investment. Buyers with long-term sourcing relationships with Indian manufacturers may see capacity expansions as PLI investments mature.
4. It's a policy in progressThe PLI scheme was announced in phases from 2020; investments are still being deployed and capacity is still coming online. The full effect on product availability and pricing will continue to develop over the coming years. Buyers should not assume PLI outcomes are immediate or universal — the impact is product-category and manufacturer-specific.
---
What It Does Not Change (For Now)
The PLI scheme does not: - Guarantee specific product availability or pricing for any individual buyer - Change regulatory requirements for GMP or export documentation - Automatically make new PLI-backed manufacturers export-ready (regulatory certification takes time regardless of incentive)
For current procurement, your supplier selection process remains the same: verify credentials, confirm GMP status, review documentation capability.
---
Staying Informed
For buyers who want to track PLI developments: - Department of Pharmaceuticals (DoP): pharmaceuticals.gov.in — publishes PLI scheme updates and beneficiary lists - Pharmexcil publishes industry commentary on PLI implications for exports - Industry publications (Pharma Times, Express Pharma, Economic Times Pharma) cover manufacturer-level developments
---
Contact Bharat Medex to discuss how India's manufacturing landscape developments affect your specific product categories and sourcing requirements.
0 comments